European commission approves adcetris®
(brentuximab vedotin) with avd, the first new treatment in decades for
adults with previously untreated cd30+ stage iv hodgkin lymphoma
Cambridge, mass. and osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) today announced that the european commission (ec) extended the current marketing authorization of adcetris (brentuximab vedotin) to include treatment of adult patients with previously untreated cd30+ stage iv hodgkin lymphoma in combination with avd (adriamycin, vinblastine and dacarbazine). adcetris is an antibody-drug conjugate (adc) directed at cd30, a defining marker of hodgkin lymphoma. the decision follows a positive opinion from the committee for medicinal products for human use (chmp) on december 13, 2018. “the decision by the european commission is a welcomed advancement for patients with previously untreated stage iv hodgkin lymphoma – a population that has not been offered a new treatment option in decades,” said anna sureda, m.d., ph.d., head of the hematology department and hematopoietic stem cell transplant programme, institut catalÀ d'oncologia – hospital duran i reynals. “patients with stage iv disease carry a higher risk of progression following their first therapy and experience poorer outcomes as a result. the approval of this regimen may help address this unmet need by providing european physicians and their patients with a new option that showed significant benefit compared to abvd along with a safety profile consistent with when adcetris is used as a single agent.” “we are pleased that the european commission has approved adcetris in combination with avd, which has the potential to represent an important milestone for patients and serves as a testament to takeda’s longstanding commitment to the hodgkin lymphoma community,” said jesÚs gÓmez-navarro, m.d., vice president, head of oncology clinical research and development, takeda. “the echelon-1 clinical trial demonstrated that the addition of adcetris and the removal of bleomycin from the standard abvd regimen yielded both efficacy and safety benefits in patients. we look forward to making this therapy available for appropriate european patients with hodgkin lymphoma.” the approval is based on the results of the randomized, open-label, two-arm, multi-center phase 3 echelon-1 study designed to compare adcetris plus avd to abvd (adriamycin, bleomycin, vinblastine and dacarbazine) as a therapy in adult patients with previously untreated hodgkin lymphoma. the trial achieved its primary endpoint resulting in a statistically significant improvement in modified progression-free survival (pfs) versus the control arm (hazard ratio [hr] 0.77; p-value=0.035), which corresponds to a 23 percent reduction in the risk of progression, death or need for additional anticancer therapy. key subgroup analyses showed a larger effect in patients with stage iv hodgkin lymphoma in the adcetris plus avd arm versus the control arm (modified pfs; hr 0.71; p-value = 0.023). the safety profile of adcetris plus avd in the echelon-1 trial was generally consistent with that known for the single-agent components of the regimen. the most common clinically relevant adverse events of any grade that occurred in at least 15 percent of patients in the adcetris plus avd and abvd arms were: neutropenia, constipation, vomiting, fatigue, peripheral sensory neuropathy, diarrhea, pyrexia, peripheral neuropathy, abdominal pain and stomatitis. in both the adcetris plus avd and abvd arms, the most common grade 3 or 4 events were neutropenia, febrile neutropenia and neutrophil count decrease. this decision by the european commission means that adcetris in combination with avd is now approved for marketing of this indication in the 28 member states of the european union and applicable in norway, liechtenstein and iceland. for further details about the european commission decision, please visit the european medicines agency website: www.ema.europe.eu/ema. about hodgkin lymphoma lymphoma is a general term for a group of cancers that originate in the lymphatic system. there are two major categories of lymphoma: hodgkin lymphoma and non-hodgkin lymphoma. hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the reed-sternberg cell. the reed-sternberg cell expresses cd30. according to the lymphoma coalition, approximately 67,000 people worldwide are diagnosed with hodgkin lymphoma each year and more than 25,000 people die each year from this cancer. up to 30 percent of previously untreated hodgkin lymphoma patients progress following their first therapy depending on the stage of the disease. only 50 percent of patients with relapsed or refractory hodgkin lymphoma achieve long-term remission with high-dose chemotherapy and an autologous stem cell transplant (asct), a historically used treatment regimen, highlighting the need for successful treatments for previously untreated patients. about adcetris adcetris is an antibody-drug conjugate (adc) comprising an anti-cd30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin e (mmae), utilizing seattle genetics’ proprietary technology. the adc employs a linker system that is designed to be stable in the bloodstream but to release mmae upon internalization into cd30-positive tumor cells. adcetris injection for intravenous infusion has received fda approval for six indications in adult patients with: (1) previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone, (2) previously untreated stage iii or iv classical hodgkin lymphoma (chl), in combination with doxorubicin, vinblastine, and dacarbazine, (3) chl at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-hsct) consolidation, (4) chl after failure of auto-hsct or failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-hsct candidates, (5) salcl after failure of at least one prior multi-agent chemotherapy regimen, and (6) primary cutaneous anaplastic large cell lymphoma (pcalcl) or cd30-expressing mycosis fungoides (mf) who have received prior systemic therapy. health canada granted adcetris approval with conditions for relapsed or refractory hodgkin lymphoma and salcl in 2013, and non-conditional approval for post-autologous stem cell transplant (asct) consolidation treatment of hodgkin lymphoma patients at increased risk of relapse or progression. adcetris received conditional marketing authorization from the european commission in october 2012. the approved indications in europe are: (1) for the treatment of adult patients with relapsed or refractory cd30-positive hodgkin lymphoma following asct, or following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option, (2) for the treatment of adult patients with relapsed or refractory salcl, (3) for the treatment of adult patients with cd30-positive hodgkin lymphoma at increased risk of relapse or progression following asct, (4) for the treatment of adult patients with cd30-positive cutaneous t-cell lymphoma (ctcl) after at least one prior systemic therapy and (5) for the treatment of adult patients with previously untreated cd30-positive stage iv hodgkin lymphoma in combination with avd. adcetris has received marketing authorization by regulatory authorities in more than 70 countries for relapsed or refractory hodgkin lymphoma and salcl. see important safety information below. adcetris is being evaluated broadly in more than 70 clinical trials, including a phase 3 study in first-line hodgkin lymphoma (echelon-1) and another phase 3 study in first-line cd30-positive peripheral t-cell lymphomas (echelon-2), as well as trials in many additional types of cd30-positive malignancies. seattle genetics and takeda are jointly developing adcetris. under the terms of the collaboration agreement, seattle genetics has u.s. and canadian commercialization rights and takeda has rights to commercialize adcetris in the rest of the world. seattle genetics and takeda are funding joint development costs for adcetris on a 50:50 basis, except in japan where takeda is solely responsible for development costs. adcetris (brentuximab vedotin) important safety information (european union) please refer to summary of product characteristics (smpc) before prescribing. contraindications adcetris is contraindicated for patients with hypersensitivity to brentuximab vedotin and its excipients. in addition, combined use of adcetris with bleomycin causes pulmonary toxicity. special warnings & precautions progressive multifocal leukoencephalopathy (pml): john cunningham virus (jcv) reactivation resulting in progressive multifocal leukoencephalopathy (pml) and death can occur in patients treated with adcetris. pml has been reported in patients who received adcetris after receiving multiple prior chemotherapy regimens. pml is a rare demyelinating disease of the central nervous system that results from reactivation of latent jcv and is often fatal. closely monitor patients for new or worsening neurological, cognitive, or behavioral signs or symptoms, which may be suggestive of pml. suggested evaluation of pml includes neurology consultation, gadolinium-enhanced magnetic resonance imaging of the brain, and cerebrospinal fluid analysis for jcv dna by polymerase chain reaction or a brain biopsy with evidence of jcv. a negative jcv pcr does not exclude pml. additional follow up and evaluation may be warranted if no alternative diagnosis can be established hold dosing for any suspected case of pml and permanently discontinue adcetris if a diagnosis of pml is confirmed. be alert to pml symptoms that the patient may not notice (e.g., cognitive, neurological, or psychiatric symptoms). pancreatitis: acute pancreatitis has been observed in patients treated with adcetris. fatal outcomes have been reported. closely monitor patients for new or worsening abdominal pain, which may be suggestive of acute pancreatitis. patient evaluation may include physical examination, laboratory evaluation for serum amylase and serum lipase, and abdominal imaging, such as ultrasound and other appropriate diagnostic measures. hold adcetris for any suspected case of acute pancreatitis. adcetris should be discontinued if a diagnosis of acute pancreatitis is confirmed. pulmonary toxicity: cases of pulmonary toxicity, some with fatal outcomes, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ards), have been reported in patients receiving adcetris. although a causal association with adcetris has not been established, the risk of pulmonary toxicity cannot be ruled out. promptly evaluate and treat new or worsening pulmonary symptoms (e.g. cough, dyspnoea) appropriately. consider holding dosing during evaluation and until symptomatic improvement. serious infections and opportunistic infections: serious infections such as pneumonia, staphylococcal bacteremia, sepsis/septic shock (including fatal outcomes), and herpes zoster, and opportunistic infections such as pneumocystis jiroveci pneumonia and oral candidiasis have been reported in patients treated with adcetris. carefully monitor patients during treatment for emergence of possible serious and opportunistic infections. infusion-related reactions (irr): immediate and delayed irr, as well as anaphylaxis, have been reported with adcetris. carefully monitor patients during and after an infusion. if anaphylaxis occurs, immediately and permanently discontinue administration of adcetris and administer appropriate medical therapy. if an irr occurs, interrupt the infusion and institute appropriate medical management. the infusion may be restarted at a slower rate after symptom resolution. patients who have experienced a prior irr should be premedicated for subsequent infusions. irrs are more frequent and more severe in patients with antibodies to adcetris. tumor lysis syndrome (tls): tls has been reported with adcetris. patients with rapidly proliferating tumor and high tumor burden are at risk of tls. monitor these patients closely and manage according to best medical practice. peripheral neuropathy (pn): adcetris treatment may cause pn, both sensory and motor. adcetris-induced pn is typically an effect of cumulative exposure to adcetris and is reversible in most cases. monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. patients experiencing new or worsening pn may require a delay and a dose reduction or discontinuation of adcetris. hematological toxicities: grade 3 or grade 4 anemia, thrombocytopenia, and prolonged (equal to or greater than one week) grade 3 or grade 4 neutropenia can occur with adcetris. monitor complete blood counts prior to administration of each dose. febrile neutropenia: febrile neutropenia has been reported with adcetris. complete blood counts should be monitored prior to administration of each dose of treatment. closely monitor patients for fever and manage according to best medical practice if febrile neutropenia develops. when adcetris is administered in combination with avd, primary prophylaxis with g-csf is recommended for all patients beginning with the first dose. stevens-johnson syndrome (sjs): sjs and toxic epidermal necrolysis (ten) have been reported with adcetris. fatal outcomes have been reported. discontinue treatment with adcetris if sjs or ten occurs and administer appropriate medical therapy. gastrointestinal (gi) complications: gi complications, some with fatal outcomes, including intestinal obstruction, ileus, enterocolitis, neutropenic colitis, erosion, ulcer, perforation and haemorrhage, have been reported with adcetris. promptly evaluate and treat patients if new or worsening gi symptoms occur. hepatotoxicity: elevations in alanine aminotransferase (alt) and aspartate aminotransferase (ast) have been reported with adcetris. serious cases of hepatotoxicity, including fatal outcomes, have also occurred. pre-existing liver disease, comorbidities, and concomitant medications may also increase the risk. test liver function prior to treatment initiation and routinely monitor during treatment. patients experiencing hepatotoxicity may require a delay, dose modification, or discontinuation of adcetris. hyperglycemia: hyperglycemia has been reported during trials in patients with an elevated body mass index (bmi) with or without a history of diabetes mellitus. closely monitor serum glucose for patients who experiences an event of hyperglycemia. administer anti-diabetic treatment as appropriate. renal and hepatic impairment: there is limited experience in patients with renal and hepatic impairment. available data indicate that mmae clearance might be affected by severe renal impairment, hepatic impairment, and by low serum albumin concentrations. cd30+ ctcl: the size of the treatment effect in cd30 + ctcl subtypes other than mycosis fungoides (mf) and primary cutaneous anaplastic large cell lymphoma (pcalcl) is not clear due to lack of high level evidence. in two single arm phase ii studies of adcetris, disease activity has been shown in the subtypes sÉzary syndrome (ss), lymphomatoid papulosis (lyp) and mixed ctcl histology. these data suggest that efficacy and safety can be extrapolated to other ctcl cd30+ subtypes. carefully consider the benefit-risk per patient and use with caution in other cd30+ ctcl patient types. sodium content in excipients: this medicinal product contains 13.2 mg sodium per vial, equivalent to 0.7% of the who recommended maximum daily intake of 2 g sodium for an adult. interactions patients who are receiving a strong cyp3a4 and p-gp inhibitor, concomitantly with adcetris may have an increased risk of neutropenia. if neutropenia develops, refer to dosing recommendations for neutropenia (see smpc section 4.2). co-administration of adcetris with a cyp3a4 inducer did not alter the plasma exposure of adcetris but it appeared to reduce plasma concentrations of mmae metabolites that could be assayed. adcetris is not expected to alter the exposure to drugs that are metabolized by cyp3a4 enzymes. pregnancy: advise women of childbearing potential to use two methods of effective contraception during treatment with adcetris and until 6 months after treatment. there are no data from the use of adcetris in pregnant women, although studies in animals have shown reproductive toxicity. do not use adcetris during pregnancy unless the benefit to the mother outweighs the potential risks to the fetus. lactation (breast-feeding): there are no data as to whether adcetris or its metabolites are excreted in human milk, therefore a risk to the newborn/infant cannot be excluded. with the potential risk, a decision should be made whether to discontinue breast-feeding or discontinue/abstain from therapy with adcetris. fertility: in nonclinical studies, adcetris treatment has resulted in testicular toxicity, and may alter male fertility. advise men being treated with adcetris not to father a child during treatment and for up to 6 months following the last dose. effects on ability to drive and use machines: adcetris may have a moderate influence on the ability to drive and use machines. undesirable effects monotherapy: the most frequent adverse reactions (≥10%) were infections, peripheral sensory neuropathy, nausea, fatigue, diarrhoea, pyrexia, upper respiratory tract infection, neutropenia, rash, cough, vomiting, arthralgia, peripheral motor neuropathy, infusion-related reactions, pruritus, constipation, dyspnoea, weight decreased, myalgia and abdominal pain. serious adverse drug reactions occurred in 12% of patients. the frequency of unique serious adverse drug reactions was ≤1%. adverse events led to treatment discontinuation in 24% of patients. combination therapy: in the study of adcetris as combination therapy with avd in 662 patients with previously untreated advanced hl, the most common adverse reactions (≥ 10%) were: neutropenia, nausea, constipation, vomiting, fatigue, peripheral sensory neuropathy, diarrhoea, pyrexia, alopecia, peripheral motor neuropathy, decreased weight, abdominal pain, anaemia, stomatitis, febrile neutropenia, bone pain, insomnia, decreased appetite, cough, headache, arthralgia, back pain, dyspnoea, myalgia, upper respiratory tract infection, alanine aminotransferase increased. serious adverse reactions occurred in 36% of patients. serious adverse reactions occurring in ≥ 3% of patients included febrile neutropenia (17%), pyrexia (6%), and neutropenia (3%). adverse events led to treatment discontinuation in 13% of patients. adcetris (brentuximab vedotin) important safety information (u.s.) boxed warning progressive multifocal leukoencephalopathy (pml): jc virus infection resulting in pml and death can occur in adcetris-treated patients. contraindication adcetris concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation). warnings and precautions peripheral neuropathy (pn): adcetris causes pn that is predominantly sensory. cases of motor pn have also been reported. adcetris-induced pn is cumulative. monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. institute dose modifications accordingly. anaphylaxis and infusion reactions: infusion-related reactions (irr), including anaphylaxis, have occurred with adcetris. monitor patients during infusion. if an irr occurs, interrupt the infusion and institute appropriate medical management. if anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. premedicate patients with a prior irr before subsequent infusions. premedication may include acetaminophen, an antihistamine, and a corticosteroid. hematologic toxicities: fatal and serious cases of febrile neutropenia have been reported with adcetris. prolonged (≥1 week) severe neutropenia and grade 3 or 4 thrombocytopenia or anemia can occur with adcetris.administer g-csf primary prophylaxis beginning with cycle 1 for patients who receive adcetris in combination with chemotherapy for previously untreated stage iii/iv chl or previously untreated ptcl.monitor complete blood counts prior to each adcetris dose. monitor more frequently for patients with grade 3 or 4 neutropenia. monitor patients for fever. if grade 3 or 4 neutropenia develops, consider dose delays, reductions, discontinuation, or g-csf prophylaxis with subsequent doses. serious infections and opportunistic infections: infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in adcetris-treated patients. closely monitor patients during treatment for bacterial, fungal, or viral infections. tumor lysis syndrome: closely monitor patients with rapidly proliferating tumor and high tumor burden. increased toxicity in the presence of severe renal impairment: the frequency of ≥grade 3 adverse reactions and deaths was greater in patients with severe renal impairment compared to patients with normal renal function. avoid use in patients with severe renal impairment. increased toxicity in the presence of moderate or severe hepatic impairment: the frequency of ≥grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment compared to patients with normal hepatic function. avoid use in patients with moderate or severe hepatic impairment. hepatotoxicity: fatal and serious cases have occurred in adcetris-treated patients. cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first adcetris dose or rechallenge. preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. monitor liver enzymes and bilirubin. patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of adcetris. pml: fatal cases of jc virus infection resulting in pml have been reported in adcetris-treated patients. first onset of symptoms occurred at various times from initiation of adcetris, with some cases occurring within 3 months of initial exposure. in addition to adcetris therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. consider pml diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. hold adcetris if pml is suspected and discontinue adcetris if pml is confirmed. pulmonary toxicity: fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. monitor patients for signs and symptoms, including cough and dyspnea. in the event of new or worsening pulmonary symptoms, hold adcetris dosing during evaluation and until symptomatic improvement. serious dermatologic reactions: fatal and serious cases of stevens-johnson syndrome (sjs) and toxic epidermal necrolysis (ten) have been reported with adcetris. if sjs or ten occurs, discontinue adcetris and administer appropriate medical therapy. gastrointestinal (gi) complications: fatal and serious cases of acute pancreatitis have been reported. other fatal and serious gi complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. lymphoma with preexisting gi involvement may increase the risk of perforation. in the event of new or worsening gi symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately. embryo-fetal toxicity: based on the mechanism of action and animal studies, adcetris can cause fetal harm. advise females of reproductive potential of the potential risk to the fetus, and to avoid pregnancy during adcetris treatment and for at least 6 months after the final dose of adcetris. most common (≥20% in any study) adverse reactions peripheral neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory tract infection, pyrexia, constipation, vomiting, alopecia, decreased weight, abdominal pain, anemia, stomatitis, lymphopenia, and mucositis. drug interactions concomitant use of strong cyp3a4 inhibitors or inducers has the potential to affect the exposure to monomethyl auristatin e (mmae). use in specific populations moderate or severe hepatic impairment or severe renal impairment: mmae exposure and adverse reactions are increased. avoid use. advise males with female sexual partners of reproductive potential to use effective contraception during adcetris treatment and for at least 6 months after the final dose of adcetris. advise patients to report pregnancy immediately and avoid breastfeeding while receiving adcetris. for additional important safety information, including boxed warning, please see the full prescribing information for adcetris at www.seattlegenetics.com or http://www.adcetris.com. about takeda pharmaceutical company limited takeda pharmaceutical company limited (tse:4502/nyse:tak) is a global, values-based, r&d-driven biopharmaceutical leader headquartered in japan, committed to bringing better health and a brighter future to patients by translating science into highly-innovative medicines. takeda focuses its r&d efforts on four therapeutic areas: oncology, gastroenterology (gi), neuroscience and rare diseases. we also make targeted r&d investments in plasma-derived therapies and vaccines. we are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative r&d engine and capabilities to create a robust, modality-diverse pipeline. our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. for more information, visit https://www.takeda.com.
